JLABS - The Future Treatment of Pulmonary Arterial Hypertension

Science 1st: The Future Treatment of Pulmonary Arterial Hypertension

December 11, 2018 | 3:30 PM - 7:30 PM

JLABS @ Toronto | 661 University Ave, Suite 1300, Toronto, ON

Advances in the diagnosis and management of PAH have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, prompt and accurate diagnosis of PAH as a rare disease remains a challenge.

Scientists and innovators today are developing the next generation of diagnostics & treatments for PAH by leveraging technologies such as stem cell therapy, gene therapy, miRNA technology, and more. But how close are we to breakthrough solutions and what are the latest developments in the space?

Join innovators developing the next generation of diagnostics & treatments for PAH. These scientific experts will share their data and insights to advance our understanding of this space, and the unique challenges they face in PAH.

Meet the speakers

Dr. Charles Bridges, MD, Sc.D.
Global Chief Technology Officer,
Actelion R&D, a Janssen Pharmaceutical company of Johnson and Johnson

Dr. John Granton, MD
Head, Division of Respirology,
University Health Network and Sinai Health System

Dr. Susanna Mak MD, PhD
Director, Mecklinger and Posluns Families Cardiac Catheterization Research Laboratory,
Anna Prosserman Heart Function Clinic

Dr. Steeve Provencher, MD, M.Sc., FRCPC
Professor of Medicine,
Laval University

$25 General Public | $15 Student